» Articles » PMID: 39351343

Retrospective Analysis of Acinetobacter Baumannii Bacteraemia Risk Factors, Complications and Mortality in a Tertiary University Hospital in Saudi Arabia

Overview
Specialty Microbiology
Date 2024 Oct 1
PMID 39351343
Authors
Affiliations
Soon will be listed here.
Abstract

There are many multidrug-resistant isolates of the nosocomial pathogen, , causing severe healthcare-acquired infections in terminally ill patients with high mortality and morbidity rates. This study aims to retrospectively analyse bacteraemia (ABB) cases in Saudi Arabia, where the information is sparse regarding the prevalence, risk factors, clinical disease, antibiotic regimen, antibiotic susceptibility, treatment outcomes and mortality associated with this infection. A retrospective chart review was conducted between 1 January 2015 and 31 December 2022 to identify all patients aged 14 years and above with ABB. Demographic and clinical data, as well as results from laboratory analyses, were collected from patients' electronic charts. Statistical analyses were performed on the data to identify factors associated with 90-day mortality. Of the 122 ABB cases, 71 (63.4%) died. The factors that were found to be associated with 90-day mortality were the Charlson Comorbidity Index, Pitt bacteraemia score, quick Sequential Organ Failure Assessment score (<0.001 for each), hospital ward (<0.02), short duration of antibiotic treatment (<0.01) and higher age (<0.05). The most common source of infection was central line-associated bloodstream infection in 52.7%. Also associated with mortality were inappropriate antimicrobial therapy (<0.02) and empirical use of colistin (<0.05). In many patients, ABB was caused by carbapenem-resistant [(CRAB), 69.6%], and 74.4% of those patients died. To prevent ABB-associated mortality, an appropriate regimen and duration of treatment are necessary. Hospitals should also practice proper hygiene to prevent the spread of ABB. CRAB is a growing threat in hospitals in Saudi Arabia, especially in the critical care setting, and carries a very high risk of mortality.

References
1.
Giamarellou H, Karaiskos I . Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients. Antibiotics (Basel). 2022; 11(8). PMC: 9394369. DOI: 10.3390/antibiotics11081009. View

2.
Chopra T, Marchaim D, Awali R, Krishna A, Johnson P, Tansek R . Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother. 2013; 57(12):6270-5. PMC: 3837851. DOI: 10.1128/AAC.01520-13. View

3.
Nucleo E, Caltagirone M, Mattioni Marchetti V, DAngelo R, Fogato E, Confalonieri M . Colonization of long-term care facility residents in three Italian Provinces by multidrug-resistant bacteria. Antimicrob Resist Infect Control. 2018; 7:33. PMC: 5839059. DOI: 10.1186/s13756-018-0326-0. View

4.
Jajoo M, Manchanda V, Chaurasia S, Sankar M, Gautam H, Agarwal R . Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India. PLoS One. 2018; 13(6):e0180705. PMC: 6023165. DOI: 10.1371/journal.pone.0180705. View

5.
Kofteridis D, Andrianaki A, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C . Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2020; 39(5):965-970. DOI: 10.1007/s10096-019-03784-9. View